3.4.2.5. minimally invasive treatment. 3.4.2.5.1. catheterisation intermittent self- third-party catheterisation preferred management neuro-urological patients cannot effectively empty bladders . adequate hand function independent risk factor cessation intermittent catheterisation (ic) . yet established whether incidence uti, complications user satisfaction affected either sterile, aseptic clean ic, coated uncoated catheters catheter type . sterile ic cannot considered routine procedure careful counselling employed commencing ic. ms, commencing ic increases uti rate one year seven fold, without improvement qol symptom score . addition, sci, dissatisfaction (and discontinuation) associated increased uti frequency, well female sex . worth considering patient satisfaction subsequent compliance instigating continuing ic. shared decision making imperative, although ic better medical outcomes indwelling catheterisation, sci population associated worse reported qol compared indwelling catheters, especially recurrent (> 4 per year) utis complicate management . use hydrophilic catheters associated lower rate uti . observational study found 56.9% patients used ic 42.1% patients discontinued ic within 12 months inconvenience (36%), leakage (20%) increased infections (19%) listed main reasons discontinuation . minimise risk uti neuro-urological patients, important patient adequately taught self-catheterise [134,245-249]. average frequency catheterisations per day four six times catheter size often used 12-16 fr. aseptic ic, optimum frequency five times showed reduction uti . ideally, bladder volume catheterisation should, rule, exceed 400-500 ml. indwelling transurethral catheterisation and, lesser extent, suprapubic cystostomy associated range complications well enhanced risk uti [134,251-258]; therefore, procedures avoided, possible. silicone catheters preferred less susceptible encrustation high incidence latex allergy neuro-urological patient population . bladder cancer might increased risk general population indwelling catheter including neuro-urological patients, clinicians promptly investigate patients standard red flags bladder cancer . 3.4.2.5.2. summary evidence recommendations catheterisation summary evidenceleintermittent catheterisation standard treatment patients unable empty bladder.3indwelling transurethral catheterisation suprapubic cystostomy associated range complications well enhanced risk uti.3 recommendationsstrength ratinguse intermittent catheterisation standard treatment patients unable empty bladder.strongthoroughly instruct patients technique risks intermittent catheterisation.strongavoid indwelling transurethral suprapubic catheterisation whenever possible.strong 3.4.2.5.3. intravesical drug treatment reduce ndo, antimuscarinics also administered intravesically . efficacy tolerability intravesical administration oxybutynin hydrochloride treatment ndo demonstrated recent randomised controlled study . approach may reduce adverse effects due fact antimuscarinic drug metabolised differently greater amount sequestered bladder, even electromotive administration . vanilloids, capsaicin resiniferatoxin, desensitise c-fibres period months . clinical studies shown resiniferatoxin limited clinical efficacy compared botulinum toxin injections detrusor . although preliminary data suggest intravesical vanilloids might effective treating neurological lut dysfunction, safety profile appears unfavourable . currently, indication use substances, licensed intravesical treatment. 3.4.2.5.4. summary evidence recommendations intravesical drug treatment summary evidencelea significant reduction adverse events observed intravesical administration oxybutynin compared oral administration.1a recommendationstrength ratingoffer intravesical oxybutynin neurogenic detrusor overactivity patients poor tolerance oral route.strong 3.4.2.5.5. botulinum toxin injections bladder botulinum toxin causes long-lasting reversible chemical denervation lasts nine months . toxin injections mapped detrusor dosage depends preparation used. botulinum toxin proven effective patients neuro-urological disorders due ms, sci pd multiple rcts meta-analyses [268-271]. mid- long-term follow-up, 50%-70% patients continue botulinum toxin treatment [272-274]. urodynamic studies might necessary treatment order monitor effect injections bladder pressure . repeated injections seem possible without loss efficacy, even initial low response rates, based years follow-up [266,276-279]. clinical efficacy botulinum toxin injection patients low morbidity failure augmentation enterocystoplasty demonstrated . effectiveness different toxin variations seems comparable . switch different toxin variations may improve responsiveness . frequent side effects utis, urinary retention haematuria . intermittent catheterisation may become necessary, especially relevant ms patients often perform ic prior intravesical botulinum toxin injections. however, lower dose botulinum toxin (100 u) may reduce rate ic ms patients . rare complications include generalised muscle weakness ad . including trigone suggested effective trigone-sparing injection . current research focuses different delivery approaches injection liposome encapsulated botulinum toxin decrease side effects . neuro-urological patients indwelling catheter concomitant bladder pain and/or catheter bypass leakage could benefit intravesical botulinum injections . 3.4.2.5.6. bladder neck urethral procedures reduction bladder outlet resistance: may necessary protect uut. achieved chemical denervation sphincter surgical interventions (bladder neck sphincter incision urethral stent â€“ section 3.4.3.1). however, high rates long-term complications still noted procedures. patients fully aware high risk urinary incontinence main reason dissatisfaction although management external devices (section 3.4.2.1). botulinum toxin a: used treat dsd effectively injecting sphincter dose depends preparation used. improvement patient reported outcomes described dsd patients cervical, incomplete sci, detrusor overactivity partial hand function . detrusor sphincter dyssynergia abolished months, necessitating repeat injections. benefit treatment reported limited mild aes . however, recent sr concluded that, limited evidence, future rcts assessing effectiveness botulinum toxin injections also need address uncertainty optimal dose mode injection . addition, therapy licensed.increasing bladder outlet resistance: improve continence condition. however, despite early positive results urethral bulking agents, relative early loss continence reported patients neuro-urological disorders .urethral inserts: urethral plugs valves management (female) stress incontinence applied neuro-urological patients. experience active pumping urethral prosthesis treatment underactive acontractile detrusor disappointing . 3.4.2.5.7. summary evidence recommendations botulinum toxin injections summary evidencelebotulinum toxin proven effective patients neuro-urological disorders due ms sci multiple rcts meta-analyses.1a recommendationsstrength ratinguse botulinum toxin injection detrusor reduce neurogenic detrusor overactivity multiple sclerosis spinal cord injury patients antimuscarinic therapy ineffective.strong